uric acid has been researched along with Parkinson Disease, Secondary in 6 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
Excerpt | Relevance | Reference |
---|---|---|
"5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia." | 3.91 | Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. ( Dohgu, S; Fukae, J; Kataoka, Y; Koga, M; Matsumoto, J; Nakashima, A; Takata, F; Tsuboi, Y; Yamauchi, A, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sarukhani, MR | 1 |
Haghdoost-Yazdi, H | 1 |
Khandan-Chelarci, G | 1 |
Nakashima, A | 1 |
Yamauchi, A | 1 |
Matsumoto, J | 1 |
Dohgu, S | 1 |
Takata, F | 1 |
Koga, M | 1 |
Fukae, J | 1 |
Tsuboi, Y | 1 |
Kataoka, Y | 1 |
De Luca, MA | 1 |
Cauli, O | 1 |
Morelli, M | 1 |
Simola, N | 1 |
Pinheiro-Carrera, M | 1 |
Tomaz, C | 1 |
Huston, JP | 1 |
Dai, H | 1 |
Carey, RJ | 1 |
Mitrović, Z | 1 |
Jusić, A | 1 |
Babucke, G | 1 |
Sagebiel, L | 1 |
Mertz, DP | 1 |
6 other studies available for uric acid and Parkinson Disease, Secondary
Article | Year |
---|---|
Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model.
Topics: Animals; Apomorphine; Biomarkers; Cell Death; Dopamine; Dopamine Agonists; Male; Neurons; Oxidative | 2018 |
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Hyperuricemia; Male; Mental Disorde | 2019 |
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration?
Topics: Animals; Dopamine; Dopaminergic Neurons; Hydroxydopamines; Male; Mice; Mice, Inbred C57BL; MPTP Pois | 2014 |
L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Levodopa; Male; Neurons; Oxidopa | 1994 |
[Spinal and bulbar amyotrophy, blepharospasm, Parkinson's syndrome and hyperuricemia].
Topics: Blepharospasm; Eyelid Diseases; Humans; Lesch-Nyhan Syndrome; Male; Middle Aged; Muscular Atrophy; P | 1979 |
[Hyperuricemia in Parkinson's syndrome--by chance or probable?].
Topics: Adult; Aged; Female; Gout; Humans; Hypertension; Levodopa; Male; Middle Aged; Obesity; Parkinson Dis | 1976 |